SciBase SEK 30m Capital Raise | Q2 2025

About SciBase 

SciBase is a global medical technology company specialising in early detection and prevention in dermatology. SciBase develops and sells Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to improve diagnostic accuracy and thereby ensure the prevention of skin diseases. 

Our commitment is to minimise patient suffering, enable doctors to improve and save lives through early detection and reduce healthcare costs.  

Based on more than 20 years of research at Karolinska Institutet in Stockholm, SciBase is a leader in dermatological development. 

Press release  

"We are very proud and pleased with both the previously announced collaboration agreement with Castle Biosciences and the fact that they are also becoming a major shareholder in SciBase. We believe this is the best outcome for SciBase and our shareholders, and we can now reach the market faster with new indications and continue to pursue our chosen strategy. In addition to Castle Biosciences, we are also very pleased to further strengthen our ownership base through an increased engagement from Danish specialist investor Life Science Invest. I am also delighted with the continued support from Haga Gruppen and Ribbskottet.", says Jesper Høiland, Chairman of the Board, SciBase. 

"Adding Castle Biosciences to our shareholder base and seeing Life Science Invest (LSI) become a major shareholder we think is a statement of strength and we believe this is very positive for all shareholders. With the collaboration agreement with Castle Biosciences, we are well positioned to deliver on our strategy of a continued expansion phase with a strong focus on the US market, where we see strong growth and high interest among clinics. We welcome our new investors and thank our existing shareholders for their continued support.", says Pia Renaudin, CEO, SciBase. 

Website: https://investors.scibase.se/en